文献速递临床试验与 GCP

亚急性甲状腺炎泼尼松龙15mg与30mg起始剂量疗效比较:多中心随机对照试验方案

Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study.
PubMed 文献 · Trials · 2020-05-24

本研究为多中心、开放、随机、平行对照试验,拟纳入90例亚急性甲状腺炎患者,随机分为泼尼松龙15mg/日组与30mg/日组,主要终点为泼尼松龙治疗所需天数,旨在验证低起始剂量非劣效且更安全。

要点

  • 亚急性甲状腺炎激素起始剂量缺乏高质量证据,本研究比较15mg与30mg泼尼松龙。
  • 主要终点为泼尼松龙治疗总天数(含复发治疗),采用非劣效设计。
  • 纳入标准为中度至重度疼痛或对足量非甾体抗炎药无效的成人患者。

核心结论

  • 旨在评估泼尼松龙15mg/日起始剂量是否非劣效于30mg/日且更安全。

研究设计与样本

  • 多中心、开放标签、随机、平行对照试验,在中国五家学术医院开展。
  • 计划纳入90例成人亚急性甲状腺炎患者,按1:1随机分配至15mg/日组或30mg/日组。

关键数值与推荐

  • 纳入标准:诊断亚急性甲状腺炎且中度至重度疼痛或对足量非甾体抗炎药无效的成人患者。
  • 主要终点:泼尼松龙治疗所需时间(天),包括复发后的泼尼松龙治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subacute thyroiditis (SAT) is the most common cause of thyroid pain. Several clinical guidelines recommend that patients who fail to respond to full doses of non-steroidal anti-inflammatory drugs (NSAIDs) should be treated instead with oral corticosteroid therapy. However, albeit strong recommendations, the treatment protocol is based on low-quality evidence and high-quality clinical trials are lacking with respect to the optimal initiation dosage and usage of corticosteroid. We aimed to evaluate whether 15 mg/day of prednisolone (PSL) as the initial dosage could provide non-inferiority effectiveness but with lower risk and more safety compared with 30 mg/day of PSL as the initial dosage. METHODS/DESIGN: This is a multicenter, open-label, randomized, parallel trial that will be conducted at five academic hospitals in China. A total of 90 adult patients diagnosed with SAT who present moderate to severe pain or fail to respond to full doses of NSAIDs will be randomly assigned with a 1:1 ratio to the low initial PSL dosage group (15 mg daily) and standard initial PSL dosage group (30 mg daily). The primary endpoint is the time period (days) required for PSL treatment (including PSL treatment for recurrence). DISCUSSION: Our randomized controlled trial will try to determine the optimal protocol in the treatment of SAT by providing high-quality evidence. TRIALS REGISTRATION: Chinese Clinical Trial Register, ChiCTR1900023884. Registered on 15 June 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xu S, Jiang Y, Jia A, et al. Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study. Trials. 2020. PMID: 32448401. doi:10.1186/s13063-020-04337-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。